Cancer, immuno-oncology, adenosine signaling, immune-checkpoints, translational research.
- Investigate the immunological pathways regulating cancer progression, metastasis and treatment response;
- Understand the role of the CD73-adenosine pathway in cancer;
- Develop new targeted cancer therapies based on immune-stimulation;
- Develop novel biomarkers in immuno-oncology;
- Translate scientific findings to clinical practice.
My group has identified the CD73-adenosinergic system as an important pathway promoting cancer growth and immune escape. We are now investigating the mechanisms underlying CD73-mediated tumor growth and immunosuppression, and the role of adenosine signaling in the progression of different types of cancers, such as breast cancer, ovarian cancer and prostate cancer. Together with our collaborators, we are pursuing drug development of novel therapeutics based on the targeted blockade of the CD73-adenosine pathway.
In addition to our basic research on CD73 and adenosine, we are studying the mechanism-of-action of immune-stimulating antibodies (including anti-PD-1, anti-PD-L1 and anti-CTLA-4 mAbs), pattern recognition receptor agonists (including Toll-like receptor agonists), and tumor-targeted antibodies (including anti-ErbB-2 mAb). The objective is to identify immune regulatory pathways associated with clinical responses and translate our findings to clinical practice.